Trial site
Augenzentrum Am St Franziskus-Hospital Muenster
Munster, 48145, GermanyNot linked to an institution yet
- 15running trials
- 4closed trials
The trials here
What the 19 trials at this site are about, from their registry records.
- Phase
- Phase 39 trials
- Phase 24 trials
- Phase 2/34 trials
- Phase 42 trials
- Status
- Active, not recruiting7 trials
- Recruiting7 trials
- Completed4 trials
- Not yet recruiting1 trial
- Lead sponsor
- Hoffmann-La Roche3 trials
- Eyebiotech Limited2 trials
- ACELYRIN Inc.1 trial
- Alexion Pharmaceuticals Inc.1 trial
- Alimera Sciences Europe Limited1 trial
- and 11 more
Running trials
Recruiting
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005)
NCT07705607· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
A randomized double-masked, multicenter, 3 arm pivotal Phase 2/3 study to evaluate the efficacy and safety of intravitreal (IVT) EYE201/MK-8748 in participants with neovascular age-related macular degeneration (NVAMD)
2025-524575-22-00· Phase 2/3· Eyebiotech Limited· Source
Recruiting
A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
NCT07441642· Phase 2· Novartis Pharmaceuticals· Source
Recruiting
A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema
NCT06962839· Phase 2· Boehringer Ingelheim· Source
Active, not recruiting
A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME
NCT06957080· Phase 2/3· EyeBiotech Ltd.· Source
Active, not recruiting
A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration
NCT06795048· Phase 4· Hoffmann-La Roche· Source
Active, not recruiting
A randomized study to evaluate the Efficacy and Safety of Intravitreal EYE103 Compared to Anti-VEGF (in patients with Diabetic Macular Edema)
2024-510944-30-00· Phase 2/3· Eyebiotech Limited· Source
Recruiting
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
NCT06541704· Phase 3· Regeneron Pharmaceuticals· Source
Recruiting
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
NCT06635148· Phase 2/3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis
NCT06431373· Phase 3· Priovant Therapeutics, Inc.· Source
Active, not recruiting
A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)
NCT06510816· Phase 3· Annexon, Inc.· Source
Active, not recruiting
ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)
NCT06373731· Phase 3· Stealth BioTherapeutics Inc.· Source
Recruiting
A Multicentre Study to Evaluate the Safety and Efficacy of the Eye Implant ILUVIEN® in Children with non-infectious uveitis affecting the posterior segment of the eye
2023-509469-19-00· Phase 4· Alimera Sciences Europe Limited· Source
Active, not recruiting
A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)
NCT04657289· Phase 3· Hoffmann-La Roche· Source
Recruiting
Extension Study for the Port Delivery System With Ranibizumab (Portal)
NCT03683251· Phase 3· Hoffmann-La Roche· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error